東陽光長江藥業(01558.HK):廣東東陽光藥業正考慮以換股方式吸收合併公司 11日復牌
格隆匯3月8日丨東陽光長江藥業(01558.HK)發佈公吿,公司已獲其母公司廣東東陽光藥業股份有限公司吿知,後者與其全資附屬公司香港東陽光銷售有限公司(公司直接股東,持有2.26億股H股,相當於公司已發行股本總額約25.71%)已於2024年3月8日訂立一份股份轉讓協議,據此,香港東陽光將根據該協議的條款及條件,向廣東東陽光藥業轉讓銷售股份,對價為每股9.14港元。股份轉讓的總對價為20.67億港元。
銷售股份所附權利與義務以及其所產生損益的轉讓,已於2024年3月8日交割。
公司已獲廣東東陽光藥業吿知,股份轉讓屬集團重組的一部份,或涉及廣東東陽光藥業與公司之間的可能合併。廣東東陽光藥業的最終實益擁有人為郭梅蘭女士及張寓帥先生,彼等共同實益擁有廣東東陽光藥業約62.12%的股權。廣東東陽光藥業的最終實益擁有人(即郭梅蘭女士及張寓帥先生)及彼等合共持有廣東東陽光藥業股權的水平在緊接及緊隨交割前後均不會有變。
公司已注意到,公司股份的價格及成交量於2024年3月1日有所增加。公司已向廣東東陽光藥業作出查詢,並瞭解到廣東東陽光藥業正考慮以換股方式吸收合併公司。廣東東陽光藥業旨在通過可能合併(1)打造研發、生產、銷售一體化的醫藥產業鏈,並通過打通國內外銷售管道打造全球領先的一體化醫藥企業;(2)通過縮短業務決策流程、降低管理成本,提高企業綜合運營效率;及(3)讓公司能夠共用廣東東陽光藥業全面完整的自主研發體系和覆蓋藥品全生命週期的研發平台,引進新產品線,確保長期增長潛力,實現長期價值創造。
廣東東陽光藥業已吿知公司,其目前建議根據可能合併,將以介紹形式在聯交所主板上市的廣東東陽光藥業的新H股提供作為公司H股的註銷價。目前正在準備可能上市的申請,備妥後將會向聯交所提交。待可能合併完成後,公司在聯交所的上市地位將會被取消。可能合併及可能上市仍處於初步階段,且難以確定可能合併或可能上市會否進行。
公司已向聯交所申請,自2024年3月11日上午九時正起恢復公司股份在聯交所的買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.